Day & Ennis’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | $682K | Buy |
23,690
+11
| +0% | +$333 | 0.24% | 69 |
|
|
2023
Q3 | $785K | Sell |
23,679
-158
| -0.7% | -$5.59K | 0.29% | 62 |
|
|
2023
Q2 | $874K | Buy |
23,837
+10
| +0% | +$389 | 0.33% | 57 |
|
|
2023
Q1 | $972K | Buy |
23,827
+9
| +0% | +$389 | 0.36% | 55 |
|
|
2022
Q4 | $1.22M | Buy |
23,818
+6
| +0% | +$288 | 0.47% | 52 |
|
|
2022
Q3 | $1.04M | Sell |
23,812
-394
| -2% | -$19.1K | 0.43% | 49 |
|
|
2022
Q2 | $1.27M | Buy |
24,206
+557
| +2% | +$28.4K | 0.48% | 48 |
|
|
2022
Q1 | $1.22M | Sell |
23,649
-143
| -0.6% | -$7.42K | 0.4% | 47 |
|
|
2021
Q4 | $1.41M | Buy |
23,792
+210
| +0.9% | +$10.4K | 0.46% | 47 |
|
|
2021
Q3 | $1.01M | Sell |
23,582
-881
| -4% | -$39K | 0.35% | 52 |
|
|
2021
Q2 | $958K | Buy |
24,463
+7
| +0% | +$272 | 0.33% | 54 |
|
|
2021
Q1 | $886K | Buy |
24,456
+895
| +4% | +$31.8K | 0.33% | 53 |
|
|
2020
Q4 | $867K | Sell |
23,561
-1,302
| -5% | -$47.8K | 0.34% | 52 |
|
|
2020
Q3 | $866K | Buy |
24,863
+298
| +1% | +$10.4K | 0.38% | 51 |
|
|
2020
Q2 | $762K | Buy |
24,565
+324
| +1% | +$11K | 0.38% | 51 |
|
|
2020
Q1 | $751K | Sell |
24,241
-426
| -2% | -$14.5K | 0.43% | 48 |
|
|
2019
Q4 | $917K | Sell |
24,667
-2,312
| -9% | -$82.4K | 0.45% | 42 |
|
|
2019
Q3 | $920K | Buy |
26,979
+69
| +0.3% | +$2.51K | 0.47% | 44 |
|
|
2019
Q2 | $1.11M | Buy |
26,910
+1,356
| +5% | +$53.8K | 0.58% | 41 |
|
|
2019
Q1 | $1.03M | Sell |
25,554
-753
| -3% | -$30.2K | 0.58% | 42 |
|
|
2018
Q4 | $1.09M | Buy |
26,307
+481
| +2% | +$20K | 0.72% | 40 |
|
|
2018
Q3 | $1.08M | Buy |
25,826
+155
| +0.6% | +$5.97K | 0.73% | 39 |
|
|
2018
Q2 | $884K | Buy |
25,671
+979
| +4% | +$33.5K | 0.66% | 41 |
|
|
2018
Q1 | $831K | Sell |
24,692
-1,883
| -7% | -$64.7K | 0.68% | 38 |
|
|
2017
Q4 | $913K | Buy |
26,575
+2,372
| +10% | +$80.9K | 0.75% | 37 |
|
|
2017
Q3 | $820K | Sell |
24,203
-5,711
| -19% | -$184K | 0.72% | 37 |
|
|
2017
Q2 | $953K | Sell |
29,914
-637
| -2% | -$20.1K | 0.82% | 31 |
|
|
2017
Q1 | $992K | Buy |
30,551
+559
| +2% | +$17.6K | 0.94% | 26 |
|
|
2016
Q4 | $924K | Buy |
29,992
+915
| +3% | +$27.9K | 0.95% | 25 |
|
|
2016
Q3 | $934K | Buy |
29,077
+1,577
| +6% | +$52.7K | 0.98% | 24 |
|
|
2016
Q2 | $919K | Buy |
27,500
+2
| +0% | +$64 | 1% | 24 |
|
|
2016
Q1 | $773K | Buy |
27,498
+2
| +0% | +$57 | 0.86% | 25 |
|
|
2015
Q4 | $842K | Buy |
+27,496
| New | +$865K | 0.94% | 24 |
|
Other funds holding PFE
Day & Ennis's PFE Position: Q4 2023 in Review
Day & Ennis increased its Pfizer (PFE) stake by 0.05% in Q4 2023, buying an estimated $333 and bringing the position to 23,690 shares worth $682K. The position accounts for 0.24% of the portfolio, ranked #69.
Day & Ennis first reported a position in PFE in Q4 2015 and has held it in 33 quarters since. The position peaked at $1.41M in Q4 2021. 2,935 funds tracked by Wall St. Rank hold PFE as of Q4 2023.
- Day & Ennis held 23,690 shares of Pfizer worth $682K as of Q4 2023.
- Day & Ennis bought 11 Pfizer shares in Q4 2023, an estimated $333.
- Pfizer made up 0.24% of Day & Ennis's portfolio in Q4 2023, its #69 holding.
- Day & Ennis first reported a position in Pfizer in Q4 2015 and has held it in 33 quarters since.
- Day & Ennis's Pfizer position peaked at $1.41M in Q4 2021.
- 2,935 funds tracked by Wall St. Rank held Pfizer as of Q4 2023.
Based on Day & Ennis's 13F filing for Q4 2023, filed 18 Jan 2024.